Medically reviewed by Adam M. Brufsky, MD, PhD The exact cause or causes of triple-negative breast cancer are unknown, but ...

An experimental vaccine could offer fresh hope to women diagnosed with an aggressive and hard-to-treat form of breas ...

University of Kentucky Markey Cancer Center researchers identified a protein that could be key to developing new treatments ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received ...

Researchers at the Center for Genomic Regulation (CRG) reveal that metabolic enzymes known for their roles in energy ...

The phase 2 INVINCIBLE-4 clinical trial is currently underway in patients with localized triple-negative breast cancer.

A groundbreaking treatment has been announced for women with an extremely aggressive form of breast cancer. Siteman Cancer ...

Researchers say the results mark the first time a vaccine - known as a neoantigen DNA vaccine - has shown such positive ...

Metabolic enzymes, typically associated with energy production, are now discovered to also play essential roles in the nucleus, such as orchestrating cell division and DNA repair. This breakthrough, ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...